Progenics Pharmaceuticals to price public offering of common shares

Bookrunner Jefferies helps raise proceeds for research and development

By Devika Patel

Knoxville, Tenn., Nov. 28 - Progenics Pharmaceuticals, Inc. plans to conduct a public offering of common stock, according to a preliminary prospectus supplement and 8-K filed Wednesday with the Securities and Exchange Commission. Jefferies & Co., Inc., the sole bookrunner, will have a 30-day greenshoe option.

Proceeds will be used for research and development and general corporate purposes.

Progenics, based in Tarrytown, N.Y., is a biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.